Icosapent ethyl significantly reduced the primary composite end point by 34% among patients with very well-controlled LDL-C. The primary outcome rate among patients with LDL-C 55 mg/dL was 16.2% ...

Icosapent Ethyl is a synthetic derivate of the omega-3 fatty acid eicosapentaenoic acid (EPA), prescribed as an adjunct to diet to reduce hypertriglyceridemia in adults.

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk ...